CEPT Inhibitors Finally Show Potential With Obicetrapib

After many setbacks, the potential for CETP inhibition to significantly improve cholesterol levels and target attainment has been shown with obicetrapib in the ROSE trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/974786?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?